Complement Alternative and Mannose-Binding Lectin Pathway Activation Is Associated With COVID-19 Mortality.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 16 07 2021
accepted: 23 08 2021
entrez: 27 9 2021
pubmed: 28 9 2021
medline: 5 10 2021
Statut: epublish

Résumé

The SARS-CoV-2 infection triggers excessive immune response resulting in increased levels of pro-inflammatory cytokines, endothelial injury, and intravascular coagulopathy. The complement system (CS) activation participates to this hyperinflammatory response. However, it is still unclear which activation pathways (classical, alternative, or lectin pathway) pilots the effector mechanisms that contribute to critical illness. To better understand the immune correlates of disease severity, we performed an analysis of CS activation pathways and components in samples collected from COVID-19 patients hospitalized in Grenoble Alpes University Hospital between 1 and 30 April 2020 and of their relationship with the clinical outcomes. We conducted a retrospective, single-center study cohort in 74 hospitalized patients with RT-PCR-proven COVID-19. The functional activities of classical, alternative, and mannose-binding lectin (MBL) pathways and the antigenic levels of the individual components C1q, C4, C3, C5, Factor B, and MBL were measured in patients' samples during hospital admission. Hierarchical clustering with the Ward method was performed in order to identify clusters of patients with similar characteristics of complement markers. Age was included in the model. Then, the clusters were compared with the patient clinical features: rate of intensive care unit (ICU) admission, corticoid treatment, oxygen requirement, and mortality. Four clusters were identified according to complement parameters. Among them, two clusters revealed remarkable profiles: in one cluster (n = 15), patients exhibited activation of alternative and lectin pathways and low antigenic levels of MBL, C4, C3, Factor B, and C5 compared to all the other clusters; this cluster had the higher proportion of patients who died (27%) and required oxygen support (80%) or ICU care (53%). In contrast, the second cluster (n = 19) presented inflammatory profile with high classical pathway activity and antigenic levels of complement components; a low proportion of patients required ICU care (26%) and no patient died in this group. These findings argue in favor of prominent activation of the alternative and MBL complement pathways in severe COVID-19, but the spectrum of complement involvement seems to be heterogeneous requiring larger studies.

Sections du résumé

Background
The SARS-CoV-2 infection triggers excessive immune response resulting in increased levels of pro-inflammatory cytokines, endothelial injury, and intravascular coagulopathy. The complement system (CS) activation participates to this hyperinflammatory response. However, it is still unclear which activation pathways (classical, alternative, or lectin pathway) pilots the effector mechanisms that contribute to critical illness. To better understand the immune correlates of disease severity, we performed an analysis of CS activation pathways and components in samples collected from COVID-19 patients hospitalized in Grenoble Alpes University Hospital between 1 and 30 April 2020 and of their relationship with the clinical outcomes.
Methods
We conducted a retrospective, single-center study cohort in 74 hospitalized patients with RT-PCR-proven COVID-19. The functional activities of classical, alternative, and mannose-binding lectin (MBL) pathways and the antigenic levels of the individual components C1q, C4, C3, C5, Factor B, and MBL were measured in patients' samples during hospital admission. Hierarchical clustering with the Ward method was performed in order to identify clusters of patients with similar characteristics of complement markers. Age was included in the model. Then, the clusters were compared with the patient clinical features: rate of intensive care unit (ICU) admission, corticoid treatment, oxygen requirement, and mortality.
Results
Four clusters were identified according to complement parameters. Among them, two clusters revealed remarkable profiles: in one cluster (n = 15), patients exhibited activation of alternative and lectin pathways and low antigenic levels of MBL, C4, C3, Factor B, and C5 compared to all the other clusters; this cluster had the higher proportion of patients who died (27%) and required oxygen support (80%) or ICU care (53%). In contrast, the second cluster (n = 19) presented inflammatory profile with high classical pathway activity and antigenic levels of complement components; a low proportion of patients required ICU care (26%) and no patient died in this group.
Conclusion
These findings argue in favor of prominent activation of the alternative and MBL complement pathways in severe COVID-19, but the spectrum of complement involvement seems to be heterogeneous requiring larger studies.

Identifiants

pubmed: 34567008
doi: 10.3389/fimmu.2021.742446
pmc: PMC8461024
doi:

Substances chimiques

Complement System Proteins 9007-36-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

742446

Informations de copyright

Copyright © 2021 Defendi, Leroy, Epaulard, Clavarino, Vilotitch, Le Marechal, Jacob, Raskovalova, Pernollet, Le Gouellec, Bosson, Poignard, Roustit, Thielens, Dumestre-Pérard and Cesbron.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Clin Immunol. 2012 Apr;143(1):22-38
pubmed: 22377282
Clin Immunol. 2020 Jun;215:108450
pubmed: 32360516
Immunotargets Ther. 2021 Jul 26;10:273-284
pubmed: 34345614
Clin Exp Immunol. 2002 Jan;127(1):131-6
pubmed: 11882043
J Infect Dis. 2021 Feb 3;223(2):214-224
pubmed: 33038254
Sci Immunol. 2021 May 13;6(59):
pubmed: 34446527
Blood. 2020 Oct 29;136(18):2080-2089
pubmed: 32877502
Cleve Clin J Med. 2020 Oct 28;:
pubmed: 33115882
Proc Natl Acad Sci U S A. 2020 Oct 6;117(40):25018-25025
pubmed: 32943538
Mol Immunol. 2002 Nov;39(7-8):465-73
pubmed: 12413698
Clin Immunol. 2021 May;226:108716
pubmed: 33774179
Lancet. 1995 Oct 7;346(8980):941-3
pubmed: 7564730
Front Immunol. 2021 Mar 25;12:663187
pubmed: 33841446
Haematologica. 2020 Jul 23;105(12):2847-2850
pubmed: 33256385
Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):4040-4047
pubmed: 32329881
Thromb Haemost. 2020 Dec;120(12):1720-1724
pubmed: 32871607
J Virol. 2010 Sep;84(17):8753-64
pubmed: 20573835
Front Immunol. 2021 Jan 29;11:594849
pubmed: 33584662
Nature. 2020 Dec;588(7836):146-150
pubmed: 32726800
J Infect Dis. 2005 May 15;191(10):1697-704
pubmed: 15838797
EClinicalMedicine. 2020 Nov;28:100590
pubmed: 33173853
Transl Res. 2020 Jun;220:1-13
pubmed: 32299776
J Immunol. 2008 Nov 15;181(10):7100-5
pubmed: 18981130
Clin Kidney J. 2020 Oct 02;13(5):889-896
pubmed: 33123364
Biomedicines. 2021 Aug 12;9(8):
pubmed: 34440207
Front Immunol. 2021 Jul 05;12:714511
pubmed: 34290717
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Clin Immunol. 2020 Oct;219:108555
pubmed: 32771488

Auteurs

Federica Defendi (F)

Laboratoire d'Immunologie, Institut de Biologie et Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

Corentin Leroy (C)

Cellule d'Ingénierie des Données, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.
Centre d'Investigation Clinique de l'Innovation et de la Technologie (CIC-IT), Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

Olivier Epaulard (O)

Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.
Université Grenoble Alpes, TIMC-IMAG, Grenoble, France.

Giovanna Clavarino (G)

Laboratoire d'Immunologie, Institut de Biologie et Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

Antoine Vilotitch (A)

Cellule d'Ingénierie des Données, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

Marion Le Marechal (M)

Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

Marie-Christine Jacob (MC)

Laboratoire d'Immunologie, Institut de Biologie et Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

Tatiana Raskovalova (T)

Laboratoire d'Immunologie, Institut de Biologie et Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

Martine Pernollet (M)

Laboratoire d'Immunologie, Institut de Biologie et Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

Audrey Le Gouellec (A)

Université Grenoble Alpes, TIMC-IMAG, Grenoble, France.
Laboratoire de Biochimie, Institut de Biologie et Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

Jean-Luc Bosson (JL)

Université Grenoble Alpes, TIMC-IMAG, Grenoble, France.

Pascal Poignard (P)

Université Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale (IBS), Grenoble, France.
Laboratoire de Virologie, Institut de Biologie et Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

Matthieu Roustit (M)

Département de Pharmacologie Clinique INSERM CIC 1406, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.
Université Grenoble Alpes, UMR 1042-HP2, INSERM, Grenoble, France.

Nicole Thielens (N)

Université Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale (IBS), Grenoble, France.

Chantal Dumestre-Pérard (C)

Laboratoire d'Immunologie, Institut de Biologie et Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.
Université Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale (IBS), Grenoble, France.

Jean-Yves Cesbron (JY)

Laboratoire d'Immunologie, Institut de Biologie et Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH